After more than 1500 gene therapy clinical trials in the past two decades, the overall conclusion is that for gene therapy (GT) to be successful, the vector systems must still be improved in terms of delivery, expression and safety. The recent development of more efficient and stable vector systems has created great expectations for the future of GT. Impressive results were obtained in three primary immunodeficiencies and other inherited diseases such as congenital blindness, adrenoleukodystrophy or junctional epidermolysis bullosa. However, the development of leukemia in five children included in the GT clinical trials for X-linked severe combined immunodeficiency and the silencing of the therapeutic gene in the chronic granulomatous disease clearly showed the importance of improving safety and efficiency. In this review, we focus on the main strategies available to achieve physiological or tissue-specific expression of therapeutic transgenes and discuss the importance of controlling transgene expression to improve safety. We propose that tissue-specific and/or physiological viral vectors offer the best balance between efficiency and safety and will be the tools of choice for future clinical trials in GT of inherited diseases.
INTRODUCTION
Gene Therapy (GT), or the introduction of genetic material with therapeutic means, is becoming a powerful tool to treat not only genetic diseases but also infectious diseases, vascular disorders and cancer. In the past decade, various viral and nonviral vectors have been engineered to improve gene delivery and more than 1500 clinical trials have been conducted. Two main conclusions can be drawn from these clinical trials: (1) it was demonstrated that GT can be of immediate clinical use for several genetic diseases; 1,2 (2) the need to improve vectors safety and efficiency before GT reaches the clinic was clearly demonstrated. New vectors must reduce genotoxicity (genomic alteration due to vector integrations), immunogenicity (immune response to gene delivery vectors and/or transgenes) and cytotoxicity (induced by ectopic expression and/or overexpression of the transgene).
Genetic diseases represent a group of rare diseases caused by mutations in one or several genes that are either transmitted from parent to child or caused by new mutations. Most mutations disrupt protein-coding genes producing a loss of function that are generally recessive (primary immunodeficiencies, cystic fibrosis, hemophilia and so on). However, in some instances, dominant mutations can create a new version of the protein with pathological functions (gain of function) as in Huntington's disease, spinal cerebellar ataxia or sickle-cell disease. To date, two therapeutic strategies have been used to tackle these two types of genetic diseases: gene addition for loss-offunction and gene silencing for gain-of-function mutations. In this review we focus on GT strategies for loss-of-function mutations.
The introduction of the cDNA coding for the correct version of the mutated gene into patients cells (gene addition) has shown better results than standard therapies for several inherited diseases including X-linked severe combined immunodeficiency (SCID), 3 adenosine deaminase deficiency, 4 chronic granulomatous disease, 5 X-linked adrenoleukodystrophy, 6 hemophilia, 7 epidermolysis bullosa and Leber's disease. 8, 9 However, in most cases, therapeutic efficacy is incomplete or comes together with serious adverse effects such as cell transformation. 10 In particular, insertional mutagenesis caused the development of T-cell acute lymphoblastic leukemia-like complications in five patients in the SCID-X1 trials. 10, 11 Further studies have shown that enhancer elements present in the retroviral backbone are important in cell transformation as they modify gene expression profiles of oncogenes present near the integration site. 12 In this sense, the more vector integration per cell, the more genes that can be affected by the vector integrations. Therefore, reducing the number of integration per cell will certainly improve safety since leukemogenesis is probably the result of multiple mutagenesis events. 11 In any case, new-generation GT vectors will need to reduce their mutagenic potential by using new viral backbones, 13 by restricting transgene expression to target cells 12 and by incorporating elements that reduce vector genotoxicity such as insulators. 14 As occurs with conventional therapeutic agents, therapeutic transgenes will have an optimal window as to where and when to exert their effects. Different inherited diseases will have different requirements depending on the nature of the affected protein(s). Some proteins are innocuous when overexpressed or when expressed in cells that do not express it normally (ectopic expression). In contrast, other proteins are very toxic and/or alter normal functions of the cells dramatically (that is, inducing transformation) interfering with the homing, proliferation or differentiation programmes of the modified cells as shown for CD40L, 15 Bruton's tyrosine kinase 16 or WAS 17 genes. In addition, some genetic diseases affect most tissues (cystic fibrosis) and others only specific cell types (red blood cells in b-thalassemia).
In this review, we examine the main strategies available to achieve physiological or tissue-specific expression of therapeutic transgenes. We focus on gene addition strategies to correct loss-of-function mutations and discuss the importance of controlling transgene expression to avoid immune responses, to reduce genotoxicity and to eliminate potential toxicity due to ectopic expression. These goals can be achieved using different strategies: (1) by using physiological or tissue-specific promoters (transcriptional targeting) to drive the expression of gene-coding cDNAs, (2) by including regulatory sequences (microRNA (miRNA) target sites) in the RNA to avoid expression in certain tissues (post-transcriptional targeting) and (3) by gene delivery strategies aiming to use the natural regulatory sequences to express the corrected gene (gene repair).
TRANSCRIPTIONAL TARGETING: TISSUE-SPECIFIC AND PHYSIOLOGICAL PROMOTERS
Most efforts to obtain tissue-specific or physiological transgene expression have focused on targeting transcription by developing gene delivery vectors harboring specific promoters. Human genes contain highly structured regulatory DNA elements that direct complex expression patterns in many different cell types during development. Although additional regulatory DNA elements (enhancers, silencers and insulators) can be scattered over distances of 100 kb, many genes contain binding sites for proximal regulatory factors located just 5¢ from the core promoter. Therefore, the incorporation of these regions into GT vectors can mediate transcriptional activation or repression of the transgene depending on the target cell. Several elements found naturally at several kb of distance from the promoter (locus control regions (LCRs), introns, enhancers or silencers) have therefore been used to increase lineage specificity. The use of insulators and matrix attachment regions is beneficial not only in terms of avoiding silencing but also improving homogeneous expression and reducing transactivation of nearby genes.
Although driving the expression of the therapeutic gene using the genes own promoter is, in theory, the most logical approach, tissuespecific expression using alternative human promoters can be more convenient and/or efficient for some approaches.
TISSUE-SPECIFIC VECTORS
Several GT strategies can benefit from targeting expression to certain tissues by either reducing toxicity (by restricting transgene expression where it is needed) or increasing efficiency (reducing immunogenicity of the transgene) ( Figure 1 ; Box 1). Viral and nonviral gene delivery vectors have been extensively used to achieve tissue-specific expression (Table 1 ). In this section we review the main tissues that have been targeted for specific expression, discussing the main applications and their advantages. Figure 1 Tissue-specific vectors main applications. Transcriptionally targeted GT vectors can be used for two purposes: to obtain expression only in the targeted tissue (localized expression) or to achieve systemic delivery of the transgene (systemic expression): Localized expression. Therapeutic transgenes can be targeted to those cells or tissues affected by the disease (CNS, Eye, epithelial cells) or in those having a function that we want to exploit (T cells, antigenpresenting cells and so on). Systemic expression. Alternatively, tissue-specific expression is also used to ensure high and sustained systemic delivery by expressing the transgene in liver, muscle endothelium or the hematopoietic system. Increased stability of transgene expression: The adequate expression levels and the use of physiologically regulated promoters can reduce gene silencing, increasing expression stability. In addition, transgene targeting to certain cell types allows the induction of tolerance to the transgene, avoiding its clearance by the immune cells. 
Liver
The liver has been targeted not only for liver disorders like the Ornithine transcarbamylase deficiency, inherited apolipoprotein A-I deficiency or chronic viral hepatitis but also for diseases that require systemic delivery of the therapeutic protein such as hemophilia, glycogen storage disease (Pompe disease), mucopolysaccharidosis and acute intermittent porphyria. 81 Targeting the liver (hepatocytes) allows not only direct access to the circulation (for systemic delivery) but can also induce tolerance to the transgene that permits longlasting expression. [81] [82] [83] [84] Natural and chimeric promoters and enhancers have been incorporated into viral and nonviral vectors to target expression of factor VIIa, factor VIII or factor IX to hepatocytes. Promoter regions from liver-specific genes such as albumin 40 and human a1 antitrypsin (hAAT) 38 are good examples of natural promoters. Alternatively, chimeric promoters have been developed to increase specificity and/or vectors efficiency. Good examples are the (ApoE)4/hAAT chimeric promoter/enhancer, 41 harboring four copies of a liver-specific ApoE/hAAT enhancer/promoter combination and the DC172 chimeric promoter, 46 consisting in one copy the hAAT promoter and two copies of the a(1)-microglobulin enhancer.
Several studies have demonstrated the advantages of liver-specific over other specific vectors to achieve sustained transgene expression of the transgenes. 81, 84 Adeno-associated virus (AAV)-mediated liverdirected GT corrected hemophilic dogs without toxicity for more than 8 years whereas in the same experiment, dogs undergoing muscle-directed GT had a bleed frequency similar to untreated hemophilic dogs. 84 Initial clinical data showing the advantages of liver directed expression come from hemophilia clinical trials in which muscle-directed injection of constitutive AAV vectors failed to show adequate therapeutic factor IX levels 85, 86 whereas portal vein injections of liver-specific AAV vectors showed some therapeutic efficacy in the highest dose. 7 However, although no immune response was observed against factor IX, its expression decreased to baseline levels by 10 weeks after infusion. The same authors demonstrated that a T-cell response against AAV capsid (not observed in large animal models) was the cause of the transient expression of factor IX in the treated patients. These experiments point out the importance of using gene delivery vectors that do not produce an immune response that will end with the destruction of gene-modified cells.
Muscle Muscle-specific vectors could theoretically be useful for muscle disorders and other pathologies requiring systemic delivery of the therapeutic genes as secreted proteins will have ready access to the circulation. Natural (creatine kinase promoter-MCK, desmin) and synthetic (a-myosin heavy chain enhancer-/MCK enhancer-promoter (MHCK7)) promoters have been included in viral and nonviral vectors to achieve efficient and specific muscle expression. 87 Pompe disease, an autosomal recessive disorder caused by deficiency of acid a-glucosidase (GAA) is an important target of muscle-specific vectors. In these patients, glycogen accumulation in the lysosomes of muscle cells (cardiac and skeletal) produce severe myopathy and cardiomyopathy. Sun et al. 54 developed a muscle-specific AAV vector (driven by the MCK or the MHCK7 promoters) that, on intramuscular injection in the GAA knockout mice, obtained important therapeutic benefits. Similar data have been obtained for muscular dystrophy. 88 Nevertheless, this strategy will need to resolve several aspects that can compromise efficiency like the immune reactions to the therapeutic gene and/or AAV capsid or the multiple intramuscular injections required to achieve adequate protein levels.
Endothelium
The vascular endothelium is an important target for GT strategies, due to its multiple roles in the pathophysiology and its direct accessibility to circulation. Endothelium-specific expression of therapeutic genes could increase efficiency and safety of GT strategies for several vascular diseases, including hypertension, atherosclerosis and ischemic artery disease. Early clinical studies have shown promise to treat several cardiovascular diseases 89 expressing therapeutic genes (VEGF, FGF and HGF) by viral (adenoviral) and nonviral (naked plasmid and liposomes) vectors. However, phase II/III studies did not confirm these initial results. 90 Endothelium-specific vectors can also be an alternative to liver-and muscle-specific vectors for systemic expression. Both natural (vWF, FLT-1 and ICAM-2) and synthetic promoters have been used to drive endothelium-specific expression by viral and nonviral vectors. 91 The combination of highly specific promoters with highly efficient vectors (adenoviral, AAV and lentiviral) 92, 93 will certainly improve initial outcomes in clinical trials of cardiovascular diseases.
Other tissues targeted for specific expression of therapeutic genes In addition to muscle, liver and endothelium (where targeted vectors can deliver the therapeutic gene to the bloodstream or to the targeted organ) several other tissues have been targeted mainly for tissuespecific expression, trying to avoid systemic delivery (Table 1) . A good example of this is the expression of laminin-5 by lentiviral vectors (LVs) containing the keratin promoter. 79 These targeted vectors are now being considered to replace murine leukemia virus-based constitutive vectors used for initial clinical trials of junctional epidermolysis bullosa, 94 a severe skin adhesion defect. The new targeted LVs showed restricted expression of laminin-5 to the basal layer of the epidermis (where it does localize in healthy individuals). Another good example is the expression of the CFTR gene (mutated in cystic fibrosis patients) using the cytokeratin 18 (KRT18) promoter. Unlike CFTR transcriptional control region, the promoter and enhancer elements controlling KRT18 expression are well characterized. Like the CFTR gene, the KRT18 expression is restricted to epithelium of internal organs. This expression pattern could be important to avoid secondary effects due to ectopic or unregulated expression of the CFTR gene. 95 In this direction, Koehler et al. 96 demonstrated that systemic administration of KRT18-driven vector targeted gene expression to CF-affected tissues. This expression cassette could therefore be a good alternative to constitutive promoters for clinical GT trials to treat CF.
PHYSIOLOGICALLY REGULATED VECTORS
Although tissue-specific vectors can be used to restrict expression to the desired tissue types, some GT approaches still require one step more in terms of transgene regulation (Box 2). Ideally, GT strategies for inherited diseases should aim to express the therapeutic transgene following the same expression pattern as in normal individuals (physiological expression). In other words, the transgene must not only be expressed in the same tissues as the endogenous gene but must also follow its expression pattern in different physiological conditions (such as T-cell activation or different stages of hematopoiesis development). Highly specific vectors have been developed for several tissue types thanks to the accessibility of well-characterized promoters and enhancer elements driving tissue-specific expression of several genes. However, the development of physiologically regulated vectors has been more difficult for two main reasons: (1) the promoter and enhancer elements must be obtained from the affected gene, (2) the gene expression pattern depends partially on the chromatin positioning.
The work carried out for GT of b-thalassemia and sickle cell disease is a good example of the difficulties found to achieve physiological transgene expression and how to overcome them. 97 Globin GT requires elevated and erythroid-specific transgene expression. In addition, as the main strategy involves reconstitution of hematopoietic stem cells (HSCs), it is important to avoid globin expression in progenitors and hematopoietic cells other than erythroid (Figure 2b) . First attempts to achieve erythroid-specific expression of the b-globin gene involved the incorporation of the b-globin LCR and 3¢ enhancers in murine oncoretroviral vectors. [98] [99] [100] [101] [102] However, the presence of large regulatory sequences in oncoretroviral vectors was limited due to its limited packaging capacity (8 kb) and to the presence of RNA sequences that favor RNA processing and therefore block the production of full-length vector-RNA molecules in producer cell lines. The first two encouraging examples of lineage-specific expression of the b-globin transgene and therapeutic efficacy were provided by May et al. 103 for b-thalassemia and by Pawliuk et al. 104 for sickle cell disease using HIV-1-based LVs. LVs allowed the incorporation of larger LCR and globin sequences (thanks to the Rev/R-responsive element) and a more efficient transduction of hematopoietic progenitors. Taking advantage of the LVs potential, May et al. 103 Other modifications to improve safety and efficiency of the therapeutic vectors consisted in the deletion of 400 bp of the LTR U3 (this avoided vector expression from the 5¢ LTR after integration) to generate a self-inactivated lentiviral vector (SIN-LV) and the inclusion of the central polypurine tract_DNA of HIV-1 (cPPT), involved in facilitating gene transfer to quiescent cells 105 (Figure 2a ). An additional improvement was provided by using SIN-LV containing the The latest vectors drive the expression of the globin gene using its own promoter and polyadenylation signals (blue), enhancers (red) and locus control regions (LCR). In addition, the chromatin insulator chicken hypersensitive site 4 (cHS4) has also been included to isolate the vector once integrated into the host genome. The introduction of these sequences allowed the vector to mimic very closely the b-globin expression pattern from healthy individuals avoiding expression in progenitor cells and in nonerythroid mature cells.
Box 2 Tissue-specific vs physiologically regulated vectors
Tissue-specific vectors: The aim of tissue-specific vectors is to restrict transgene expression to one cell or tissue type. This has been achieved using a multitude of vectors and tissue types (see Table 1 ) using any tissue-specific promoter to drive the expression of the therapeutic transgene.
Physiologically regulated vectors: These vectors are more rigorous in terms of expression pattern than tissue-specific vectors. The aim is to achieve a similar expression pattern as the affected gene in healthy individuals. Therefore, for a particular inherited disease only the promoter and enhancer sequences of the affected gene can be used. If the affected gene is expressed constitutively in only one cell type, then tissue-specific and physiologically regulated vectors will be almost identical. However, in most cases gene expression is subjected to developmental and environmental modulation that only physiologically regulated vectors can mimic.
For a particular GT strategy, the decision of using tissue-specific or physiologically regulated vectors will be dictated by the activity and the expression pattern of the protein affected in the pathology in which we are working.
same regulatory elements as mentioned above and replacing a fragment of 398 bp of the U3 region with the chromatin insulator chicken hypersensitive site 4 with the aim of conferring position-independent expression. 14,106 Recently Perumbeti et al. 107 showed the therapeutic potential of these vectors in a Berkeley 'humanized' sickle cell mouse (mice expressing exclusively human sickle hemoglobin). This mouse model has the major features found in sickle cell disease patients and represents a useful in vivo system to accelerate the development of new therapies. The author used this model to determine the parameters needed for achieving therapeutic activity with minimal HSCs modification and minimal conditioning.
Wiskott-Aldrich syndrome (WAS) GT is another good example of how physiologically regulated vectors have been pursued to increase biosafety aspects of gene delivery vectors. GT vectors for WAS must be well regulated, as transgene expression will be needed in the whole hematopoietic lineage, at a certain concentration depending on the cell type. Recently, we have shown that overexpression of WASP protein in nonhematopoietic cells reduces cell viability by disturbing the cytoskeleton. 17 Moreover, overexpression of WAS gene homologues may contribute to cancer cell invasion and metastasis. 108, 109 This points out the importance of GT vectors with the capacity to express the transgene in the right cells, at the right levels. Several groups, including ours, have developed SIN-LV that express the WAS cDNA specifically in hemotopoietic cells using different fragments of the WAS gene proximal promoter. 18, 19, 110 Our group has shown that a 500 bp fragment of the WAS proximal promoter was enough to obtain a very strong hematopoietic-restricted expression of WAS (up to 300 times) 18 and a strong reduction of side effects due to ectopic expression. 17 Similar hematopoietic specificity was observed when a 1600 bp fragment of the proximal promoter was used. 19 Importantly, these physiologically regulated vectors were able to correct immune and cytoskeletal defects in WAS knockout mice 111 as well as efficiently transduce and correct hematopoietic stem cells from WAS patients. 112 In addition, Baum's group 113 demonstrated that WAS-promoterdriven LVs expressing WASP protein had no transformation potential using a sensitive cell culture assay. With these safety and efficacy profiles in animal models, WAS-promoter-driven LVs are now approved for phase I/II clinical trials (http://www.genethon.fr/ index.php?id¼334). Though the increase in safety of the vector selected for the WAS trial is clear, the question of to which extent this vector is able to express WASP protein following the endogenous WAS gene expression pattern must still be investigated. In this sense our group demonstrated that the 500 bp of the proximal promoter is not enough to achieve a physiologically regulated expression of the transgene (using eGFP as a marker gene) and that a downregulation of the expression (compared to endogenous WAS) in some myeloid cell types can be observed. 114 In this work, we also show that introduction of sequences of the WAS alternative promoter (found 5 kb upstream of the WAS proximal promoter in the genome) could partially overcome this defect. Only the completion of the ongoing clinical trial will tell us whether it is necessary to include additional regulatory sequences in the final therapeutic vector.
Several other therapeutic vectors harboring physiological promoters have been developed for GT for diseases such as muscular dystrophy, 115 Leber's congenital amaurosis 8 and familial hypercholesterolemia 116 (Table 2) .
POST-TRANSCRIPTIONAL TARGETING: miRNA TARGET SITES Tissue-specific and/or physiologically regulated expression can also be pursued by modifying mRNA stability and/or translation efficiency (post-transcriptional targeting) of the trasngenes. RNA targeting has mainly been used to downregulate expression of cellular genes using GT vectors expressing RNAi (revised elsewhere 123, 124 ). Alternatively, RNA targeting strategies can also be used to control the expression of the GT vectors. Specifically, the incorporation of miRNA target recognition sites (miRTs) into the expressed mRNA has been used to block transgene expression (detargeting) in specific tissues or cell types. 125 Basically, this strategy harnesses the endogenous cellular machinery to knock down the expression of the transgene expressed by the vector (Figure 3) . miRNAs are endogenously expressed noncoding RNAs, approximately 22 nucleotides in length that modulate a diverse array of cellular activities. They are fully or partially complementary to the 3¢ UTR region of particular mRNA, referred to as miRTs. Binding of an miRNA to its particular miRTs promotes translational attenuation/inactivation and/or degradation. miRNA distribution analysis has revealed that each cell contains a diverse population of miRNA and that the abundance of individual miRNA species varies greatly between different cell lineages and different tissues (Figure 3a) . Engineering miRTs-vector recognized by a specific miRNA cell type has been shown to be an effective way for knocking down the expression of a therapeutic gene in undesired cell types (Figure 3b ). This strategy was first used by Brown et al. 126 to obtain expression of green fluorescent protein (GFP) specifically in nonhematopoietic cells. The authors used LVs expressing a modified-GFP cDNA carrying four copies of the hematopoietic-specific miRNA mir-142 target sequence (expressed in hematopoietic cells). In a second report Brown et al. 127 used the same strategy to show reconstitution of a mouse model of hemophilia B, by in vivo delivery of LVs expressing the human factor IX. In both cases, the aim was to prevent the expression of the foreign gene by antigen-presenting cells 126, 127 to avoid activation of specific lymphocyte responses to transgene products. In a similar approach, Papapetrou et al. 128 demonstrated specific expression of foreign genes only in post-thymic naive or activated T cells by incorporating mirR-181a target sequence (expressed in developing T cells) in the therapeutic vector. Recently the Naldini's group 129 has demonstrated that this strategy can be used to tolerize rodents to a lentiviral-encoded antigen. They demonstrated that mice inoculated with an miR-142-regulated vector encoding GFP do not develop an anti-GFP response after GFP vaccination and that the mechanism probably involved the induction of GFP-specific regulatory T cells.
ALTERNATIVE APPROACHES: EXON SKIPPING AND GENE REPAIR Exon skipping
Exon skipping uses antisense oligonucleotides to alter normal splicing. It can be used to block aberrant splice sites restoring normal splicing, to promote alternative splice sites to benefit expression of beneficial isoforms or to produce nonfunctional mRNAs to block expression of a dominant-negative mutation. 130 The delivery of the antisense oligonucleotides can be carried out by viral 131 or nonviral 132, 133 vectors.
One remarkable success of exon skipping was reported by van Deutekom et al. 133 in four patients with Duchenne muscular dystrophy. The authors showed that intramuscular injection of antisense oligonucleotide (PRO051) produced specific skipping of the mutated exon and achieved 3-12% of the dystrophin levels found in healthy individuals. However, to have a realistic therapeutic effect, repeated systemic treatment will be required to increase and maintain therapeutic protein levels. To tackle this point, we can use viral vectors (meanly AAV) to achieve systemic expression of the antisense oligonucleotide. 131 In fact, Denti et al. 131 showed that systemic delivery of AAV by intravenous injection in animal models resulted in a broad dispersion and transduction of muscles that showed a significant recovery of function toward normal values. This approach provides solid bases for clinical trials for Duchenne muscular dystrophy using viral vectors to achieve exon skipping.
Gene repair
The repair of defective genes (directly in the cellular genome) requires the substitution of a DNA molecule (introduced into a cell) for the corresponding mutated DNA segment by homologous recombination. This is certainly the safest way to cure inherited diseases as the 'in situ' correction of the mutation(s) will reconstitute normal physiological gene function and will warrant sustained expression of the repaired gene through its endogenous promoter. Nevertheless, site-specific engineering of the human genome has been limited by the low frequency of homologous recombination and by the use of drug selection. Recently, improvements in DNA delivery technology and in the development of customized zinc-finger nucleases (ZFN) 134 and meganucleases 135 has awaken new interest in this technology for their use in GT approaches. In particular, ZFNs combine the nonspecific cleavage of endonucleases with the specific recognition properties of zinc-finger proteins to cut at the desired chromosomal locus inside the Figure 3 Targeting vector mRNA as a tool to modulate gene expression. (a) Different miRNAs are expressed specifically in some cell types (green) but not others (red). These miRNAs are processed to render tissue-specific siRNAs that are incorporated into the RISC complex to form the effector complex that target mRNAs containing microRNA target sequences (miRTs) (b). Gene expression driven by a vector can be modulated at post-transcriptional level by including in the vector backbone several copies of miRTs recognized by tissue-specific miRNAs. The transgene expression driven by the vector will be blocked in cells where the miRNA is expressed (green) but will not modify the expression in those cells that do not express it (red).
cells. Once the target DNA has been cut, the cells own homologousdirected repair mechanism uses the delivered DNA to correct the gene defect. Using this principle, it is found that ZFNs are very efficient for stimulating homology-directed gene repair in a variety of cell types. The accuracy and high efficiency of the homologous recombination process combined with the ability to design ZFNs that target most DNA sequences makes this technology a powerful tool for gene manipulation. Recent results have shown that ZFNs can be used to create targeting frequencies from 5 to 50% in the absence of selection in several cell lines 136 including primary T cells.
In spite of their potential, both efficacy and efficiency must be further improved before this technology can be applied in clinic. Several possible side effects can be envisioned as a result of gene modification by ZFNs. Small insertions and/or deletions can occur by DNA repair through nonhomologous end-joining. 137 Although the extent of this genotoxicity can be lowered by increasing specificity 138 or reducing ZFNs expression levels, 139 in-depth analysis must be performed to determine the extent and potential dangers of this technology. The use of cell culture transformation assays 140 and animal models 12 to study transformation potential will help determine how safe this strategy is compared to the use of retroviral vectors to express the correct version of the gene.
THERAPEUTIC IMPLICATIONS
We think that subsequent successful clinical trials for inherited diseases will involve tissue-specific and/or physiologically regulated viral vectors. They present, for now, the best balance between efficiency and safety. Although other GT strategies such as gene repair are very promising, they need to be further analyzed before reaching the clinic. The main advantages of tissue or physiologically regulated viral vectors are the reduced genotoxicity and/or the increased stability of transgene expression (principal problems of inherited GT clinical protocols) maintaining transduction efficiency. In addition, regulated viral vectors will minimize the potential side effects caused by overexpression or by ectopic expression of the therapeutic transgene.
CONCLUDING REMARKS
The primary goal of GT for inherited diseases is to repair the genetic defect in the cells affected by the mutated gene. By doing so, we would reconstitute the wild-type expression of the mutated gene obtaining good therapeutic benefits without secondary effects. However, although the technology to achieve gene repair is available, it is not efficient enough to get therapeutic benefits in animal models of human disease. For now, gene therapists aiming for clinic intervention of inherited diseases have focused their effort on the stable introduction of foreign genetic material to express the therapeutic transgenes, which is more efficient but theoretically less safe than gene repair. Indeed, the first GT successes using integrative viral vectors came together with several undesired side effects such as cell transformation. Next generations of GT clinical trials for inherited diseases should aim to maintain or increase efficiency while reducing the occurrence of undesired side effects.
Several improvements in vector development have made GT tools safer and more efficient. In this direction, the main safety concern has been cellular transformation that can occur in consequence to oncogene activation by vector enhancers. New cellular 140 and animal 13 models have been developed to study genotoxicity potential of integrative vectors. Using these models, several groups have demonstrated the increase in safety of SIN vectors 12, 141 and better performance of lentiviral over murine leukemia-based vectors. 13 In addition, although it was largely hypothesized that regulated expression should also reduce genotoxicity, Baum's group 113 recently demonstrated that tissue-specific and physiologically regulated vectors are indeed safer with no detectable transforming potential. However, the insertional mutagenesis due to vector integration represents a potential hazard to target cells that is still present when using these vectors.
In this review, we have focused on how to control gene expression to obtain safer and more efficient viral vectors. Some therapeutic proteins must be expressed systemically and therefore the aim is to target expression to tissues allowing efficient and long-lasting transgene expression into the bloodstream (liver, muscle and endothelium). If the disease is caused by a mutation in a gene that is constitutively expressed in a certain tissue, a tissue-specific promoter (not necessarily its own gene promoter) should be used. For some other diseases, in which the mutated gene is not only tissue specific but is also regulated during development or by extrinsic factors, it is important to use physiologically regulated vectors. These vectors must express the therapeutic transgene efficiently and follow the same expression pattern as the endogenous gene in a healthy individual. Important advances have also been obtained in gene repair technology. Scientists have achieved good efficiencies of targeted gene modifications (including gene repair) in important targets such as primary T cells and embryonic stem cells. Future experiments must demonstrate therapeutic benefits in animal models of genetic diseases before this technology can be proposed as a therapeutic alternative to gene addition using viral vectors.
